Optima Formula BV

21/10/2026

Helaas hebben de providers onze sites plat gelehd wegens het php data lek. Wat er al is sinds 2012 overigens, bestellen kan alleen via www.optimaformula.nl en via email. We hopen zo snel mogelijk weer online te zijn.

C*D olie bestellen, C*D olie kopen, CBN olie, CBG olie, cannabidiol, cannabinoiden en voedingssupplementen van hoogwaardige kwaliteit. C*D olie, CBG olie, CBN olie, CBC olie, of breed spectrum c*d olie bestellen. OptimaFormula bekend van de Optima C*D olie. Kwaliteit is ons motto.

12/10/2026

A newly published study just made inflammatory pain research more interesting by putting CBN and THCV beside C*D instead of letting isolated C*D carry the whole cannabinoid conversation.

“Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain” (May 2026) found that C*D, CBN, and THCV all reduced mechanical pain sensitivity in rats with knee inflammation, while CBN also reduced heat sensitivity and THCV helped restore body weight.

In plain language, these cannabinoids showed pain-related effects in an inflammatory pain model, but they didn't all act the same way.

Researchers used a CFA knee-injection model in male rats to create joint inflammation, tissue damage, reduced movement, increased mechanical pain, and some thermal sensitivity. One week later, the rats received four daily doses of ibuprofen, C*D, CBN, or THCV.

The goal was to see whether these plant cannabinoids could reduce inflammatory pain and how they compared with a common anti-inflammatory drug.

The strongest takeaway is that CBN and THCV stood out. All three cannabinoids reduced mechanical hyperalgesia, but CBN also lowered thermal hypersensitivity. CBN and THCV helped recover body weight in the inflamed animals, while C*D reduced body weight and raised blood monocyte and granulocyte levels above the inflamed control group.

That doesn't make C*D bad. It means different cannabinoids may behave differently depending on the pain model, dose, immune state, and biology involved.

For consumers, this study does not prove that CBN or THCV treats arthritis or inflammatory pain in humans. It does show why cannabinoid science needs to move beyond one-cannabinoid thinking.

For industry and researchers, CBN and THCV deserve deeper study in inflammatory pain, especially where pain, immune activity, and movement are all part of the same problem.

-Mike Robinson, Global Cannabinoid Research Center

Study: https://doi.org/10.1038/s41598-026-51275-7

11/10/2026

A newly published study is hitting one of pain medicine’s hardest questions - can C*D help opioids work better without adding more reward-driven risk?

“Selective opioid-sparing effects of cannabidiol on opioid analgesia in rats” (May 2026) found that C*D enhanced the pain-relieving effect of oxycodone in rats, without increasing oxycodone-related reward behaviors under the conditions tested.

In plain language, C*D appeared to make oxycodone work better for pain, but did not make the opioid more rewarding in the behavioral models used.

Researchers studied this because opioids still matter for moderate to severe pain, but higher doses can bring serious problems - side effects, tolerance, dependence risk, and misuse liability.

The study tested C*D at 3.2 and 10.0 mg/kg with oxycodone at 0.56 mg/kg in male and female Sprague-Dawley rats, using an operant facial pain assay, locomotor monitoring, and conditioned place preference testing.

The key finding is the separation between pain relief and reward behavior. C*D enhanced oxycodone’s antinociceptive effect, meaning it improved pain-signal control in the model, but it did not change oxycodone-induced rearing behavior or conditioned place preference.

That matters because pain medicine needs better ways to reduce opioid load without leaving patients suffering.

For consumers, this does not mean C*D should be mixed with opioids without a clinician. It means cannabinoid research is moving toward smarter adjunct strategies that may someday help patients use less opioid while keeping meaningful pain relief.

For science and industry, this is a clear signal - C*D and other cannabinoids deserve serious study as opioid-sparing tools, with dosing, safety, interactions, and human trials handled with real medical discipline.

-Mike Robinson, Global Cannabinoid Research Center

Study:

Cannabidiol, a major non-intoxicating constituent of cannabis, has generated interest as a novel therapeutic for managing several pathological conditions including chronic pain and opioid use disorder. Here, we evaluated the effects of cannabidiol (3.2 or 10.0 mg/kg) on the antinociceptive and the r...

06/10/2026

Inflammation is supposed to protect the body, not take over the whole house. When inflammatory signaling stays turned on, it can damage tissue, drive pain, disturb immunity, and push the ECS, our Master Regulator, into a state of constant response instead of clean regulation.

“Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action” (2022) breaks down how cannabis compounds interact with inflammatory biology through cannabinoids, terpenes, flavonoids, immune cells, receptors, and signaling pathways.

The review points out that the ECS modulates immune activity, and when that system becomes dysregulated, chronic inflammation can become part of the disease process.

This is where cannabinoids get interesting. THC, C*D, and CBG are all discussed as phytocannabinoids with anti-inflammatory activity in experimental models.

They may act through CB1, CB2, TRPV channels, GPR receptors, PPARs, serotonin receptors, and adenosine pathways, while also influencing inflammatory mediators like TNF-alpha, IL-1 beta, IL-6, COX-2, iNOS, nitric oxide, ROS, MAPK, NF-kB, and related immune cascades.

That’s not “weed helps inflammation” science. That’s plant chemistry touching the body’s command lines for immune response, oxidative stress, cytokine release, and inflammatory resolution.

Researchers highlighted the synergy between phytocannabinoids and terpenes, showing why whole-plant thinking still matters, even when targeted active ingredients are selected.

The takeaway is clean - cannabis isn’t one anti-inflammatory molecule. It’s a library of plant-derived bioactives that may help guide immune signaling back toward balance when inflammation refuses to shut off.

-Mike Robinson Global Cannabinoid Research Center



Study:

Inflammation often develops from acute, chronic, or auto-inflammatory disorders that can lead to compromised organ function. Cannabis (Cannabis sativa) has b...

28/09/2026

CBG. We voeren het reeds sinds 2018.

Obesity isn’t just stored fat sitting there doing nothing - it’s a cellular program. Fat cells are built, filled, protected, inflamed, and metabolically defended through gene signals that can keep the body stuck in storage mode long after willpower has left the building.

In “Comparative Anti-Obesity Potential of Cannabigerol-Dominant Cannabis sativa L. Inflorescence Extracts via Differential Regulation of Lipid Metabolism in 3T3-L1 Cells” (2026), researchers tested CBG-dominant Cannabis sativa extracts in 3T3-L1 cells, a standard fat-cell model used to study adipocyte development. The extract contained seven identified cannabinoids, with cannabigerol as the major constituent, giving this study a direct CBG-centered metabolic focus.

What matters here is mechanism. The CBG-dominant extracts dose-dependently inhibited fat-cell differentiation and pushed down key adipogenic and lipogenic markers, including PPARγ, C/EBPα, SREBP-1c, and FAS. That means the cells weren’t just storing less fat by accident - signals tied to fat-cell formation and lipid production were being turned down.

Then the other side of the metabolic switch lit up. The extracts increased markers tied to lipolysis and white adipose tissue browning, including HSL, ATGL, UCP1, and PGC-1α. In plain language, the cells showed signals connected to breaking down stored fat and shifting white fat toward a more energy-burning profile. That’s where cannabinoid research gets interesting - not as diet hype, but as cellular metabolism science.

This doesn’t mean CBG is a weight-loss shortcut. It means cannabinoids may influence metabolic pathways that decide whether cells build fat, store fat, break fat down, or move toward energy use. That’s a much smarter conversation than pretending obesity is just a plate problem.

The ECS, our Master Regulator, is tied to appetite, energy storage, insulin behavior, inflammation, and cellular balance. CBG is now stepping into that metabolic conversation with data showing it may help shift fat-cell biology away from storage and toward regulation.
Optima Formula BV
Credits;

-Mike Robinson, Global Cannabinoid Research Center

Study:

Obesity is a chronic metabolic disorder characterized by excessive accumulation of body fat and is a major risk factor for various diseases, including type 2 diabetes, hypertension, and cardiovascular diseases. This study investigated the anti-obesity effects of cannabigerol-dominant C. sativa inflo...

24/09/2026

Pijn of moeilijk inslapen. Probeer onze bestseller CBN. www.cannabinoideshop.nl

21/09/2026

Hoe ontspannend was jouw weekend? wat is jouw favoriete manier om te ontspannen in het weekend? 🌱 Laat het weten in de comments!

20/09/2026

20/09/2026

THCV, de "sportieve" cannabinoïde
THCV (tetrahydrocannabivarine) is een minder bekende, maar interessante cannabinoïde die momenteel volop onderzocht wordt. In tegenstelling tot THC werkt het heel anders in het lichaam. Nieuwsgierig? Wij volgen het onderzoek op de voet.
👉 Lees meer:

C*D olie van OptimaFormula bevatten het meest zuivere extract C*D olie afkomstig van 100% biologische planten. Bekijk het hele assortiment hier: